Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer

Clinical Cancer Research

Volumn 16, Issue 16, 2010, Pages 4165-4177

  Arcaroli, John J ^a   Touban, Basel M ^a   Tan, Aik Choon ^a   Varella Garcia, Marileila ^a   Powell, Rebecca W ^a   Eckhardt, S Gail ^a   Elvin, Paul ^b,c   Gao, Dexiang ^b,c   Messersmith, Wells A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FOCAL ADHESION KINASE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PROTEIN TYROSINE KINASE; SARACATINIB; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE NUMBER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZODIOXOLES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955760833     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0066     Document Type: Article

References (50)

1. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004;23: 7957-68.
2. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002;1602:114-30.
3. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000;100:293-6.
4. Summy J, Gallick G. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58.
5. LaVallee T, Prudovsky I, McMahon G, Hu X, Maciag T. Activation of the MAP kinase pathway by FGF-1 correlates with cell proliferation induction while activation of the Src pathway correlates with migration. J Cell Biol 1998;141:1647-58.
6. Peterson J, Kulik G, Jelinek T, Reuter C, Shannon J, Weber M. Src phosphorylates the insulin-like growth factor type I receptor on the autophosphorylation sites. Requirement for transformation by Src. J Biol Chem 1996;271:31562-71.
7. Rahimi N, Hung W, Tremblay E, Saulnier R, Elliott B. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J Biol Chem 1998;273:33714-21.
8. Tice D, Biscardi J, Nickles A, Parsons S. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A 1999;96:1415-20.
9. Hauck C, Hsia D, Schlaepfer D. The focal adhesion kinase: a regulator of cell migration and invasion. IUBMB Life 2002;53:115-9.
10. Jones RJ, Brunton VG, Frame MC. Adhesion-linked kinases in cancer;emphasis on src, focal adhesion kinase and PI 3-kinase. Eur J Cancer 2000;36:1595-606.
11. Schaller M. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochimica et Biophysica Acta 2001; 1540:1-21.
12. Owens L, Xu L, Craven R, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 1995;55: 2752-5.
13. Niu G, Wright K, Huang M, et al. Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000-8.
14. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81-3.
15. Wong CH, Baehner FL, Spassov DS, et al. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res 2009;15:2311-22.
16. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-38.
17. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-61.
18. Messersmith WA, Rajeshkumar NV, Tan AC, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther 2009;8:1484-93.
19. Rajeshkumar NV, Tan AC, De Oliveira E, et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 2009;15:4138-46.
20. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
21. Yeatman T. A renaissance for src. Nat Rev Cancer 2004;4:470-80.
22. Malek RL, Irby RB, Guo QM, et al. Identification of Src transformation fingerprint in human colon cancer. Oncogene 2002;21:7256-65.
23. Cartwright C, Meisler A, Eckhart W. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci U S A 1990;87:558-62.
24. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993;91:53-60.
25. Park J, Meisler A, Cartwright C. c-Yes tyrosine kinase activity in human colon carcinoma. Oncogene 1993;8:2627-35.
26. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
27. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80.
28. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360: 563-72.
29. Irby R, Mao W, Coppola D, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999;21:187-90.
30. Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008;68: 1953-61.
31. Dangles-Marie V, Pocard M, Richon S, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 2007; 67:398-407.
32. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
33. Tan AC, Naiman DQ, Xu L, Winslow RL, Geman D. Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics 2005;21:3896-904.
34. Dreyfus GMG. Withdrawing an example from the training set: an analytic estimation of its effect on a non-linear parameterised model. Neurocomputing 2000;35:195-201.
35. Green TP, Fennell M, Whittaker R, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 2009;3: 248-61.
36. Golas JM, Lucas J, Etienne C, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005;65:5358-64.
37. Serrels A, Macpherson IR, Evans TR, et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006;5:3014-22.
38. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9.
39. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27:6365-75.
40. Le Naour F, Andre M, Greco C, et al. Profiling of the tetraspanin web of human colon cancer cells. Mol Cell Proteomics 2006;5: 845-57.
41. Hosking CR, Ulloa F, Hogan C, et al. The transcriptional repressor Glis2 is a novel binding partner for p120 catenin. Mol Biol Cell 2007;18:1918-27.
42. Barlund M, Monni O, Weaver JD, et al. Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer 2002;35:311-7.
43. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087-93.
44. Funato Y, Miki H. Nucleoredoxin, a novel thioredoxin family member involved in cell growth and differentiation. Antioxid Redox Signal 2007;9:1035-57.
45. Lee M, Vasioukhin V. Cell polarity and cancer-cell and tissue polarity as a non-canonical tumor suppressor. J Cell Sci 2008;121: 1141-50.
46. Nanashima A, Yamaguchi H, Yasutake T, et al. Gain of chromosome 20 is a frequent aberration in liver metastasis of colorectal cancers. Dig Dis Sci 1997;42:1388-93.
47. Jimeno AAS, Karikari C, Garrido-Laguna I, et al. A prospective validation of a direct tumor xenograft model in pancreatic ductal adenocarcinoma (PDA). J Clin Oncol 2008;26:4500.
48. Fogelman DR, Kopetz S, Eng C. Emerging drugs for colorectal cancer. Expert Opin Emerg Drugs 2008;13:629-42.
49. Kopetz SRAW, Glover K, Henry L, et al. Phase I study of Src inhibition with dasatinib in combination with 5-fluoruracil, leucovorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. ASCO-2008 Gastrointestinal Cancers Symposium 2008;325.
50. Kopetz S, Lesslie DP, Dallas NA, et al. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009;69:3842-9.